Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults
Executive Summary
The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.